User profiles for B Graves
Barbara GravesUniversity of Utah Verified email at utah.edu Cited by 13472 |
Barriers and motivations to exercise in older adults
KA Schutzer, BS Graves - Preventive medicine, 2004 - Elsevier
Although exercise is an established component in the management of many chronic diseases
associated with aging, activity levels tend to progressively decline with increasing age. …
associated with aging, activity levels tend to progressively decline with increasing age. …
[HTML][HTML] International society of sports nutrition position stand: caffeine and performance
Position Statement: The position of The Society regarding caffeine supplementation and
sport performance is summarized by the following seven points: 1.) Caffeine is effective for …
sport performance is summarized by the following seven points: 1.) Caffeine is effective for …
Genomic and biochemical insights into the specificity of ETS transcription factors
…, LP McIntosh, BJ Graves - Annual review of …, 2011 - annualreviews.org
… On the basis of the crystallographic structure of a single ELF3 ETS domain bound to the B
site of a tandem type II TGF-B receptor promoter, enhanced binding of a second ELF3 to the …
site of a tandem type II TGF-B receptor promoter, enhanced binding of a second ELF3 to the …
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev, BT Vu, B Graves, D Carvajal, F Podlaski… - Science, 2004 - science.org
… The enantiomers of Nutlin-3 (a and b) were separated with … and chemical properties,
enantiomer-b is 150 times less potent … Enantiomer-b had no effect regardless of the p53 status of …
enantiomer-b is 150 times less potent … Enantiomer-b had no effect regardless of the p53 status of …
Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region
Cell signaling that culminates in posttranslational modifications directs protein activity. Here
we report how multiple Ca 2+ -dependent phosphorylation sites within the transcription …
we report how multiple Ca 2+ -dependent phosphorylation sites within the transcription …
Isolation of a recombinant copy of the gene encoding C/EBP.
… shows, anti-peptide serum led to the selective precipitation of a DNAbinding activity that was
capable of producing DNase I footprints on the two enhancer core motifs of the hepatatis B …
capable of producing DNase I footprints on the two enhancer core motifs of the hepatatis B …
[HTML][HTML] Gender differences in perceived stress and coping among college students
BS Graves, ME Hall, C Dias-Karch, MH Haischer… - PloS one, 2021 - journals.plos.org
Background Many college students register each semester for courses, leading to productive
careers and fulfilled lives. During this time, the students have to manage many stressors …
careers and fulfilled lives. During this time, the students have to manage many stressors …
[BOOK][B] Teaching Reading in the 21st Century.
MF Graves, C Juel, BB Graves - 1998 - ERIC
Melding what has been learned from research, theory, and experience, this book presents a
comprehensive plan for assisting students in becoming lifelong readers and attaining the …
comprehensive plan for assisting students in becoming lifelong readers and attaining the …
Discovery of RG7388, a potent and selective p53–MDM2 inhibitor in clinical development
…, K Packman, LT Vassilev, B Graves - Journal of medicinal …, 2013 - ACS Publications
… “Cis–Cis” or “Trans–Trans” refers to the relative orientation between ring A vs ring B and
R vs ring A. endo (“down”) and exo (“up”) refers to the position of Cγ in relation to Cα. …
R vs ring A. endo (“down”) and exo (“up”) refers to the position of Cγ in relation to Cα. …
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof …
…, N Penel, J Zhi, F Heil, R Rueger, B Graves… - The lancet …, 2012 - thelancet.com
Background We report a proof-of-mechanism study of RG7112, a small-molecule MDM2
antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or …
antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or …